Jul 29, 2019 17:49 JST

Source: NEC Corporation

NEC Acquires Norwegian Bioinformatics Company, OncoImmunity AS

TOKYO, Jul 29, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.

OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable time frame.

NEC announced its business strategy surrounding its AI-driven drug discovery business in May 2019. This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.

Sharing a common vision, both NEC and OncoImmunity AS firmly believe in improving individualized cancer treatments through Artificial Intelligence (AI). AI holds great promise in enabling each and every patient to receive the most appropriate medication.

"The OncoImmunity AS team are delighted to be joining the NEC Group and firmly believe that the union will realize great synergies, marrying the mutual strengths of OncoImmunity AS's and NEC's neoantigen prediction pipelines with NEC's expertise in AI, data management and security. These synergies will help strengthen NEC's individualized immunotherapy programs, whilst simultaneously positioning NEC OncoImmunity AS as the leading neoantigen prediction service provider in the field," said Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity AS.

"NEC strongly believes that healthcare based on genomics paves the way for individualized medicine. OncoImmunity AS is a recognized player in the neoantigen prediction field, and their compelling systems are expected to form valuable synergies with NEC. We are confident that this acceleration of development will provide promising new avenues that lead to better cancer treatments," said Osamu Fujikawa, Senior Vice President, NEC Corporation.

Contact:
NEC 
Seiichiro Toda         
s-toda@cj.jp.nec.com 
+81-3-3798-6511
Source: NEC Corporation
Sectors: CyberSecurity

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Stripe and NEC to Provide Face Recognition Payment Service via Stripe Terminal
November 06 2025 16:30 JST
 
NEC and Siemens collaborate to accelerate smart factory innovation
November 04 2025 23:57 JST
 
NEC and e& Sign MoU to Drive Joint Sustainability Initiatives
October 30 2025 21:46 JST
 
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
October 30 2025 13:18 JST
 
NEC Achieves Cisco Gold Provider Status, Strengthening Global Strategic Partnership in the AI era
October 28 2025 21:09 JST
 
NEC and the Cote d'Ivoire Ministry of Agriculture enhance agricultural efficiency through digital technology
October 22 2025 19:55 JST
 
NEC Security to Provide Cybersecurity Services for GREENxEXPO 2027 (International Horticultural Expo 2027,Yokohama, Japan)
October 03 2025 22:01 JST
 
Ouribank Signs Agreement with NEC to Implement AI-Native Data Center and Campus Network from HPE Juniper Networking for Enhanced Operational Efficiency
September 30 2025 18:52 JST
 
NEC Releases Third Edition of TNFD Report
September 29 2025 15:24 JST
 
NEC Launches 25Gb/s SFP28 Bi-directional Optical Transceiver Capable of 80km Transmission
September 26 2025 20:20 JST
 
More Press release >>

Latest Press Release


More Latest Release >>